Variant Bio

Right on the heels of our press release announcing a deal with Novo Nordisk, we're thrilled to see this NY Times coverage of the partnership and Variant Bio's ethics-first approach to drug discovery: nytimes.com/2025/01/07/hea…

Coverage of Variant Bio's collaboration with Prof. Lyn Griffiths and the QUT Centre for Genomics and Personalised Health on the genetic and multi-omic landscape of metabolic conditions in Pasifika communities in Australia: #google_vignette" target="_blank" rel="nofollow noopener">miragenews.com/2-1m-queenslan…

Variant Bio recently launched a study with Novo Nordisk, this time in partnership with the University of Otago and Pukapuka Community Group: medium.com/variantbio/kic…

We published an open-access article on how to apply flexible benefit-sharing models to genomic research projects in South Africa and beyond: medium.com/variantbio/col…

An anthropologist and a geneticist from Variant Bio teamed up with partners in New Caledonia to return study results one island at a time: medium.com/variantbio/by-…

Coverage in @geekwire's Tech Moves today (geekwire.com/2026/tech-move…):

We are thrilled to welcome Dr. Craig Basson to our team at Variant Bio! Read more here: prnewswire.com/news-releases/…

Coinciding with our most recent pharma collaboration, we officially launched our Inference agentic AI platform and an accompanying website: medium.com/variantbio/var…

@VariantBio and Boehringer Ingelheim are teaming up to advance research focused on kidney diseases Read the full story here 👇 healthtechnologyinsights.com/variant-bio-pa…

1/ Big news today from Lux family co Variant Bio 🧬📈@VariantBio Announced its new Inference platform is now available to research partners + has collaborations with several pharmaceutical companies in deals totaling more than $200 million including Boehringer + Novo Nordisk...

2/ Variant Bio @VariantBio has just revealed inference.bio the world's first agentic AI genomic discovery platform

Harnessing genomics and AI agents in drug discovery, platform underpins new kidney disease collaboration with Boehringer Ingelheim. longevity.technology/news/variant-b… #longevity #biotech #drugdiscovery #AI #pharma

#more-23105" target="_blank" rel="nofollow noopener">timmermanreport.com/2026/01/varian…

By combining our AI Inference platform with Boehringer’s expertise, we’re turning global genetic insights into real-world impact for patients. A massive milestone for our team! 🚀

Variant Bio recently kicked off another new study with Novo Nordisk, this time in Samoa in partnership with Oceania University of Medicine: medium.com/variantbio/pro…

Prof. Lyn Griffiths from Queensland University of Technology visited Norfolk Island to check in on benefit-sharing initiatives: medium.com/variantbio/var…

In our newest publication in @TrendsGenetics, we argue for the importance of tailoring research results according to cultural context and community input: medium.com/variantbio/var…

We recently joined the team from the Mochtar Riady Institute for Nanotechnology to share research results with communities in Java and Bali: medium.com/variantbio/var…

“We may have traveled in different boats, but we’re all on the same ship.” — Words of wisdom from @VariantBio’s collaborator Dr. Herawati Sudoyo at the Asia-Pacific Conference for Human Genetics in Yogyakarta, Indonesia last week, together with the amazing team from MRIN:

We joined research partners in Tahiti to kick off recruitment for an expansion of Variant Bio’s 2022 collaborative study with GHICL: medium.com/variantbio/lau…